Responding to a Broad Agency Announcement (BAA-NIAID-DMID-NIHAI2012149) solicitation titled “Development of Therapeutic Medical Countermeasures for Biodefense and Emerging Infectious Diseases”, VenatoRx has been selected to execute a research and development contract around proprietary compounds that address resistant NIAID Category A, B, and C pathogens. The contract award is for up to $21.2M.